title: IBD: Infliximab dose optimization in IBD-proactive or reactive?
authors.affiliation: IBD Unit, Internal Medicine and Gastroenterology, Complesso Integrato Columbus, Catholic University, Via Moscati, 31-33, 00168 Rome, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Armuzzi
authors.affiliation: IBD Unit, Internal Medicine and Gastroenterology, Complesso Integrato Columbus, Catholic University, Via Moscati, 31-33, 00168 Rome, Italy.
authors.forename: Carla
authors.initials: C
authors.lastname: Felice
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D011379:Prognosis
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D000069285:Infliximab